Prevalence, associated factors and antifungal susceptibility patterns of Candida auris bloodstream infection among adult intensive care unit patients at a tertiary hospital in Tanzania: a cross-sectional study
This cross-sectional study at a tertiary hospital in Tanzania found a 2.15% prevalence of multidrug-resistant *Candida auris* bloodstream infections among adult ICU patients, identifying prolonged hospital stays and immunosuppression as key risk factors while highlighting significant resistance to fluconazole and variable susceptibility to other antifungals.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the high-stakes environment of a hospital intensive care unit, patients are fighting for their lives against severe illnesses, often relying on machines and tubes to survive. While doctors and nurses work tirelessly to treat these conditions, the hospital itself can sometimes become a breeding ground for microscopic invaders. Among the most dangerous of these are fungi, a type of microorganism that includes common yeasts. Usually, these organisms are harmless or easily treated, but a specific, newly recognized strain called Candida auris has emerged as a formidable threat. Unlike its relatives, this yeast is notorious for its ability to survive on hospital surfaces for long periods, spread easily between patients and staff, and resist many of the standard medicines used to kill it. Because it is so difficult to treat and so hard to stop from spreading, understanding where it lives and how it behaves is critical for protecting the most vulnerable people in our healthcare systems.
In Tanzania, where data on this specific fungus was previously scarce, a team of researchers set out to uncover the reality of Candida auris in their local intensive care unit. Working at the Benjamin Mkapa Hospital in Dodoma, they focused on adult patients who had been admitted to the general intensive care unit for more than two days and showed signs of a bloodstream infection. Over a four-month period in early 2026, the team collected blood samples from 186 such patients. To ensure they were identifying the correct organism, they used advanced laboratory technology that acts like a fingerprint scanner for microbes, allowing them to distinguish Candida auris from other similar yeasts with high precision. They also tested how these specific bacteria responded to common antifungal drugs, checking whether the medicines would work or if the fungus had developed defenses against them.
The investigation revealed that Candida auris was indeed present in this setting, though not in overwhelming numbers. The researchers found the fungus in the blood of four patients, which translates to a prevalence of roughly two percent among the group studied. This discovery is significant because it confirms that the fungus is circulating in Tanzanian hospitals, a fact that was previously uncertain. More importantly, the study identified who was most at risk. The data showed that patients who stayed in the intensive care unit for a week or longer were significantly more likely to develop this infection. Similarly, patients whose immune systems were weakened by other conditions faced a much higher risk. These factors appeared to be independent drivers of the infection, meaning that even when other variables were considered, a long hospital stay and a weakened immune system remained strong predictors of the disease.
The behavior of the fungus itself offered a stark warning about treatment options. When the researchers tested the four identified strains against standard antifungal medications, the results were mixed but concerning. Every single one of the four strains was completely resistant to fluconazole, a very common drug used to treat fungal infections. This means that if a doctor prescribed this standard medication, it would likely fail to clear the infection. The situation with other drugs was more complex. Two of the four strains were resistant to amphotericin B, another powerful antifungal, while the other two could still be treated with it. Regarding caspofungin, a third type of drug, three of the four strains responded well, but one strain had developed resistance. This pattern suggests that while some treatment options remain, the fungus is already showing the ability to fight back against multiple types of medication.
The study concludes that while the number of cases found was small, the presence of this drug-resistant fungus in a major Tanzanian hospital is a serious matter that requires immediate attention. The findings highlight that patients who are critically ill and stay in the hospital for extended periods are the most vulnerable. The researchers emphasize that to manage this threat, hospitals need to improve their ability to identify the fungus quickly and accurately, rather than relying on older methods that might miss it or misidentify it. Furthermore, they stress the need for strict infection control measures to prevent the fungus from spreading between patients and for doctors to carefully choose which medicines to use, ensuring that the few effective drugs available are not wasted. By understanding the local patterns of this infection, healthcare providers can better protect their patients and prevent a small number of cases from growing into a larger outbreak.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.